Results for isoenzimi translation from Maltese to English

methylnaltrexone huwa metabolizzat mill- inqas b’ isoenzimi cyp.
methylnaltrexone is minimally metabolised by cyp isozymes.

għalkemm jista ’ jkun li isoenzimi oħrajn għandhom rwol sekondarju.
in vitro studies with human liver microsomes suggest that oxidative metabolism of nevirapine is mediated primarily by cytochrome p450 isozymes from the cyp3a family, although other isozymes may have a secondary role.

l- effett ta ’ etoricoxib fuq mediċini metabolizzati minn isoenzimi cyp
effect of etoricoxib on drugs metabolised by cyp isoenzymes

olanzapine ma jimpedixxix l-isoenzimi cyp450 prinċipali in vitro (eż.
olanzapine does not inhibit the main cyp450 isoenzymes in vitro (e.g.

14 phenytoin, phenobarbital, u antikonvulsivi oħra li huma sottostrati ta ’ isoenzimi cyp450
phenytoin, phenobarbital, and other anticonvulsants that are substrates of cyp450 isoenzymes

bosentan hu inducer taċ- ċitokromju p450 (cyp) isoenzimi cyp2c9 u cyp3a4.
bosentan is an inducer of the cytochrome p450 (cyp) isoenzymes cyp2c9 and cyp3a4.

studji in-vitro wrew li delamanid ma jimpedixxix l-isoenzimi ta’ cyp450.
in-vitro studies showed that delamanid did not inhibit cyp450 isozymes.

l-isoenzimi ta’ ċitokrom p450 mhumiex involuti fil- metaboliżmu ta’ telmisartan.
the cytochrome p450 isoenzymes are not involved in the metabolism of telmisartan.

palonosetron ma jinibixxix jew jikkaġuna isoenzimi taċ-ċitokrom p450 f’konċentrazzjonijiet li huma klinikament relevanti.
palonosetron does not inhibit or induce cytochrome p450 isoenzymes at clinically relevant concentrations.

anidulafungin mhux sottostrat, induttur, jew inibitur klinikament rilevanti ta’ isoenzimi taċ-ċitokromu p450.
anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome p450 isoenzymes.

cyp3a4/5 huma l-isoenzimi prinċipalment responsabbli għall-eliminazzjoni metabolika ta’ olaparib.
cyp3a4/5 are the isozymes predominantly responsible for the metabolic clearance of olaparib.

voriconazole huwa metabolizzat pemezz ta ’ l- isoenzimi ta ’ cytochrome p450, cyp2c19, cyp2c9 u cyp3a4.
voriconazole is metabolised by cytochrome p450 isoenzymes, cyp2c19, cyp2c9 and cyp3a4.

palonosetron jiġi metabolizzat primarjament minn cyp2d6, b’kontribuzzjoni żgħira mill-isoenzimi ta’ cyp3a4 u cyp1a2.
palonosetron is mainly metabolised by cyp2d6, with minor contribution by cyp3a4 and cyp1a2 isoenzymes.

għalhekk, interazzjonijiet minħabba l-inibizzjoni jew l- induzzjoni ta’ l-isoenzimi cyp450 mhumiex mistennija.
hence, interactions due to inhibition or induction of cyp450 isoenzymes are not expected.

għandha tkun ikkunsidrata l-possibbiltà li l-effikaċja ta’ prodotti mediċinali metabolati minn dawn l-isoenzimi tinbidel.
the possibility of altered efficacy of medicinal products metabolised by these isoenzymes should be considered.

isoenzimi ta’ ċitokromu p450 cyp2d6, cyp2c19, cyp2c9 u cyp2a6 huma involuti f’demetilizzazzjoni-o ta’ formoterol.
cytochrome p450 isoenzymes cyp2d6, cyp2c19, cyp2c9 and cyp2a6 are involved in the o-demethylation of formoterol.

avanafil jitneħħa primarjament mill-isoenzimi mikrosomali epatiċi cyp3a4 (rotta ewlenija) u cyp2c9 (rotta minuri).
avanafil is cleared predominantly by the cyp3a4 (major route) and cyp2c9 (minor route) hepatic microsomal isoenzymes.

studji in vitro dwar l-interazzjoni ma wrew l-ebda inibizzjoni jew induzzjoni ta’ l-isoenzimi prinċipali ta’ ċitokrom p450.
in vitro interaction studies did not show any inhibition or induction of the principal isoenzymes of cytochrome p450.

methylnaltrexone bromide ma jaffettwax il-farmakokinetiċi ta’ prodotti mediċinali oħrajn metabolizzati bl-isoenzimi p450 (cyp) ta’ cytochrome.
methylnaltrexone bromide does not affect the pharmacokinetics of medicinal products metabolised by cytochrome p450 (cyp) isozymes.

inibizzjoni ta’ dawn l-isoenzimi tista’ żżid il- konċentrazzjoni ta’ bosentan fil-plażma (ara ketoconazole).
inhibition of these isoenzymes may increase the plasma concentration of bosentan (see ketoconazole).